PAMED COVID-19 Briefing:
May 17, 2022
FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
The FDA has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine. Read more.
PAMED is updating the Briefing section of our
COVID-19 page. This is where we’ll put the top updates that have happened. If you’d like to receive an email or text when an update is available, you can sign up for either below.